Loading clinical trials...
Loading clinical trials...
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Conditions
Interventions
NBI-98854
Locations
10
United States
Neurocrine Clinical Site
Anaheim, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Neurocrine Clinical Site
Gulf Breeze, Florida, United States
Neurocrine Clinical Site
Hialeah, Florida, United States
Neurocrine Clinical Site
Chicago, Illinois, United States
Neurocrine Clinical Site
Naperville, Illinois, United States
Start Date
October 17, 2018
Primary Completion Date
February 18, 2019
Completion Date
February 18, 2019
Last Updated
April 19, 2022
NCT06678737
NCT03851484
NCT04449068
NCT05558566
NCT06194305
NCT06873841
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions